The firm originally submitted the application seeking approval for TLX101-Px in August 2024, but the agency requested additional efficacy analysis.
Sarepta plans to evaluate the gene therapy with a new immunosuppressive regimen in the hopes of relaunching it in the non-ambulatory indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results